Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase II Study of Apalutamide plus/minus Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging

Trial Profile

A Randomized, Phase II Study of Apalutamide plus/minus Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Apalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PILLAR
  • Most Recent Events

    • 21 Dec 2018 Planned initiation date changed from 1 Dec 2018 to 1 Mar 2019.
    • 19 Oct 2018 Planned initiation date changed from 1 Jul 2018 to 1 Dec 2018.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top